Patent ID: 6489299
Filing Date: 2002-12-03
Classification: A61K,A61P,C07K

Abstract:
A pharmaceutical composition for treating multiple sclerosis comprising a peptide analogue comprising amino acid residues 87-99 of myelin basic protein, wherein the lysine residue at position 91 is altered to another amino acid, in combination with a physiologically acceptable carrier or diluent, wherein the peptide analogue competes for binding of MBP (87-99) to major histocompatibility complex, does not cause proliferation of an MBP (87-99) reactive T cell line, and inhibits induction of experimental allergic encephalomyelitis by MBP (87-99) in rodents and wherein said composition does not contain said peptide analogue in the form of a noncovalent complex with a Major Histocompatibility Complex (MHC) component.